X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the X4 Pharmaceuticals fourth quarter and full year 2024 financial and operating results conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference call is being recorded, and it is now my pleasure to turn to your host, Dan Ferry from LifeSite Advisors. Please begin. Thank you, Operator, and good morning, everyone. Presenting on today's call will be X4's Chief Executive Officer, Dr. Paula Regan, and Chief Financial Officer, Adam Mostafa. Following prepared remarks by each, we will open the call to your questions, and we'll be joined by Chief Commercial Officer, Mark Baldry, Chief Medical Officer, Dr. Christoph Arvid Engels, and Chief Operating Officer, Mary DiBiase. As a reminder on today's call, the company will be making forward-looking statements regarding regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in X4's most recent filings with the SEC, including this year's Form 10-K, which is expected to be filed after market close today. I'd now like to turn the call over to X4's President and CEO, Dr. Paula Regan. Paula? Thank you, Dan, and thanks to all of you for joining us this morning. As expected, 2024 was a transformative year for the company and for those with WHIM syndrome, and we are very pleased to continue to deliver as we progress into 2025. As you know, we became a fully integrated company in 2024 with the U.S. approval and launch of our first product, Maverick Zephyr, which we branded as the remedy in the US for the treatment of WHIM syndrome, an ultra-rare primary i...